We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Stemedica announced today that it has signed a Licensing Agreement with Pulthera, LLC for the rights to use, distribute and sell its mesenchymal stem cell technologies in the treatment of COVID-19 and additional pulmonary conditions.